Collectively known as GLP-1 agonists, these drugs mimic the hormone GLP-1
(MOQ 5, high sales volume)
Semaglutide (Wegovy/Ozempic) at 2.4mg produces 14.9% over 68 weeks
Extracted data included title, trial name, the first author, publication year, country/region, dose, administration route, median follow-up time, sample size, age, sex, race, body mass index (BMI), smoke, blood pressure, glycated hemoglobin (HbA1c), T2DM duration, estimated glomerular filtration rate (eGFR), baseline CVD or CKD, and measures of effect assessed by the hazard ratio (HR) and its 95% confidence interval (CI) for each of the cardiovascular outcomes
The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language
Semaglutide starts GLP-1 receptors mainly in the hypothalamus, very the arcuate nucleus and paraventricular nucleus, regions crucial for regulating energy balance and food intake
